Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Unoh, Yuto; Uehara, Shota; Nakahara, Kenji; Nobori, Haruaki; Yamatsu, Yukiko; Yamamoto, Shiho; Maruyama, Yuki; Taoda, Yoshiyuki; Kasamatsu, Koji; Suto, Takahiro; Kouki, Kensuke; Nakahashi, Atsufumi; Kawashima, Sho; Sanaki, Takao; Toba, Shinsuke; Uemura, Kentaro; Mizutare, Tohru; Ando, Shigeru; Sasaki, Michihito; Orba, Yasuko; Sawa, Hirofumi; Sato, Akihiko; Sato, Takafumi; Kato, Teruhisa; Tachibana, Yuki

doi:10.1021/acs.jmedchem.2c00117

articleJournal of Medicinal ChemistryMar 30, 2022HYBRID OA

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

YUYuto Unoh SUShota Uehara KNKenji Nakahara HNHaruaki Nobori YYYukiko Yamatsu

Shionogi (Japan) · Futaba (Japan) · +1 more institution

PubMed

Indexed incrossrefdatacitepubmed

Abstract

Dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, indicating that this novel noncovalent inhibitor could be a potential oral agent for treating COVID-19.

Citation impact

583

total citations

FWCI: 82.04
Percentile: 100%
References: 34

Citations per year

Authors

25

Topics & keywords

Topics

Keywords

Pharmacology
Protease inhibitor (pharmacology)
Pharmacokinetics
Dosing
Coronavirus disease 2019 (COVID-19)
In vivo
Virtual screening
Virology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.

Funding

S
Shionogi